Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

232
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
232
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

208
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
208
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

355
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
355
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

437
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
437
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

234
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
234

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Health status of living kidney donors and attitude toward donation-Results from the German Living Donor Registry (SOLKID-GNR).

Frontiers in medicine·2026
Same author

Pathogen-specific epidemiology and clinical trajectories of fungal infections after kidney transplantation: a prospective multicenter cohort study.

BMC infectious diseases·2026
Same author

[Medication during heatwaves].

MMW Fortschritte der Medizin·2026
Same author

Long-Term Outcomes Across Age and Risk Profiles in a Caucasian Living Kidney Donor Cohort.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

A UPLC-MS/MS assay for the quantification of the novel viral helicase-primase drug candidate adibelivir (IM-250) in human specimen.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2026
Same author

Age-Related Risk After Kidney Transplantation: A Comprehensive Analysis of Infection Burden, Graft Outcomes, and Mortality.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

[Progression inhibition in chronic kidney disease].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Optimal blood pressure control in patients with diabetes and arterial hypertension: interpreting the BPROAD study].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Distributive justice in healthcare during times of change: a medical ethics perspective].

Innere Medizin (Heidelberg, Germany)·2026
查看所有相关文章

相关实验视频

Updated: Jan 16, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.8K

[多种药物和毒性]

David Czock1, Kathrin Ebinger2, Claudia Sommerer3

  • 1Innere Medizin IX - Abteilung für Klinische Pharmakologie und Pharmakoepidemiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. david.czock@med.uni-heidelberg.de.

Innere Medizin (Heidelberg, Germany)
|January 14, 2026
PubMed
概括
此摘要是机器生成的。

在老年人中,多药可以导致脏损伤. 了解药物相互作用和"毒负担"的概念可以帮助评估和管理风险,以改善脏健康.

关键词:
急性损伤是什么?急性损伤是什么?药物诱导的毒性 药物诱导的毒性毒性负担 毒性负担药理动力学药物相互作用药物相互作用 药物相互作用 药物相互作用

更多相关视频

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.9K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K

相关实验视频

Last Updated: Jan 16, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.8K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.9K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K

科学领域:

  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 临床药理学 临床药理学
  • 老年病的医生 老年病的医生

背景情况:

  • 多药性在老年人中很普遍,增加了脏不良影响的风险.
  • 药物诱导的毒性可以表现为功能变化或结构管状损伤.

研究的目的:

  • 系统地审查与多药学相关的毒性.
  • 为了确定影响脏的药理动力学和药理动力学药物相互作用.
  • 为风险评估引入和评估"毒负担"的概念.

主要方法:

  • 进行了选择性的文献综述.
  • 专注于药物诱导的毒性和影响功能的药物相互作用.

主要成果:

  • 药物动力学相互作用 (例如,CYP3A4抑制) 可以提高毒药物水平 (例如,氨酸抑制剂).
  • 药理动力学相互作用 (例如,NSAIDs,ACE抑制剂,利尿剂) 可能导致效应.
  • "毒负担"概念量化了多种毒药物引起的AKI风险,但需要机制差异化.

结论:

  • 对新处方的仔细审查和药物监测对于服用氨酸抑制剂的患者至关重要.
  • 同时使用具有结构管状毒性的药物增加了风险;功能相互作用 (例如,ACE抑制剂和SGLT2抑制剂) 经常被容忍.
  • "毒负担"概念显示出风险分层的潜力,但需要进一步验证.